Abstract
Tuberculosis is a major infectious disease in the world, which causes high mortality. The treatment consists of drugs of first and second line; however, its effectiveness is limited by several factors, mainly the presence of resistant and/or multi-drug resistant strains. This work reviews compounds derived from quinoxaline 1, 4-dioxide with antimycobacterial activity in in vitro and in vivo models as an option for the development of new drugs against tuberculosis.
| Translated title of the contribution | Quinoxaline 1,4-dioxide: A viable option for the development of antitubercular drugs |
|---|---|
| Original language | Spanish |
| Pages (from-to) | 17-23 |
| Number of pages | 7 |
| Journal | Revista Mexicana de Ciencias Farmaceuticas |
| Volume | 46 |
| Issue number | 2 |
| State | Published - 1 Apr 2015 |